Understanding why tuberculosis treatment takes so long and how to improve it
Drug tolerance, bacterial heterogeneity and adverse TB treatment outcomes
This study is looking into why treating tuberculosis (TB) takes so long and why some people don't get better, focusing on how certain bacteria can resist the medicine; the goal is to find ways to make treatment easier and more effective for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10874613 on NIH RePORTER |
What this research studies
This research investigates the reasons behind the lengthy treatment process for tuberculosis (TB), which typically requires six months of multi-drug therapy. It focuses on understanding how certain bacterial factors contribute to treatment failure and relapse, particularly looking at drug tolerance and resistance in Mycobacterium tuberculosis. The study employs advanced techniques to analyze bacterial behavior and genetic factors that may lead to prolonged treatment and adverse outcomes. By identifying these mechanisms, the research aims to develop strategies to enhance treatment effectiveness and adherence.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with active tuberculosis who are undergoing or about to begin multi-drug therapy.
Not a fit: Patients with latent tuberculosis or those who have already completed TB treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to shorter and more effective TB treatment regimens, improving patient outcomes and adherence.
How similar studies have performed: Previous research has shown promise in understanding drug resistance in tuberculosis, but this approach is exploring novel methodologies that have not been extensively tested.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Sherman, David R — Rutgers Biomedical and Health Sciences
- Study coordinator: Sherman, David R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.